Morgan Stanley’s Aquestive Therapeutics AQST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.74M | Sell |
658,617
-933,175
| -59% | -$3.93M | ﹤0.01% | 4659 |
|
|
2026
Q1 | $6.61M | Sell |
1,591,792
-166,958
| -9% | -$678K | ﹤0.01% | 3910 |
|
|
2025
Q4 | $11.4M | Buy |
1,758,750
+348,641
| +25% | +$2.17M | ﹤0.01% | 3503 |
|
|
2025
Q3 | $7.88M | Sell |
1,410,109
-3,952
| -0.3% | -$17.1K | ﹤0.01% | 3761 |
|
|
2025
Q2 | $4.68M | Sell |
1,414,061
-113,228
| -7% | -$325K | ﹤0.01% | 4106 |
|
|
2025
Q1 | $4.43M | Buy |
1,527,289
+790,400
| +107% | +$2.39M | ﹤0.01% | 4026 |
|
|
2024
Q4 | $2.62M | Buy |
736,889
+65,400
| +10% | +$302K | ﹤0.01% | 4512 |
|
|
2024
Q3 | $3.34M | Buy |
671,489
+115,503
| +21% | +$449K | ﹤0.01% | 4272 |
|
|
2024
Q2 | $1.45M | Buy |
555,986
+463,064
| +498% | +$1.55M | ﹤0.01% | 4764 |
|
|
2024
Q1 | $396K | Buy |
92,922
+68,757
| +285% | +$229K | ﹤0.01% | 5416 |
|
|
2023
Q4 | $48.8K | Buy |
24,165
+8,228
| +52% | +$14.5K | ﹤0.01% | 6173 |
|
|
2023
Q3 | $24.4K | Sell |
15,937
-5,932
| -27% | -$10.2K | ﹤0.01% | 6427 |
|
|
2023
Q2 | $36.1K | Buy |
21,869
+17,199
| +368% | +$31.1K | ﹤0.01% | 6342 |
|
|
2023
Q1 | $5.32K | Sell |
4,670
-1,002
| -18% | -$868 | ﹤0.01% | 7036 |
|
|
2022
Q4 | $5.12K | Sell |
5,672
-27,709
| -83% | -$26K | ﹤0.01% | 7140 |
|
|
2022
Q3 | $39K | Buy |
33,381
+13,517
| +68% | +$15.3K | ﹤0.01% | 6514 |
|
|
2022
Q2 | $13K | Sell |
19,864
-76,269
| -79% | -$101K | ﹤0.01% | 7129 |
|
|
2022
Q1 | $250K | Sell |
96,133
-99,389
| -51% | -$290K | ﹤0.01% | 5790 |
|
|
2021
Q4 | $760K | Sell |
195,522
-50,626
| -21% | -$254K | ﹤0.01% | 5271 |
|
|
2021
Q3 | $1.07M | Sell |
246,148
-307,579
| -56% | -$1.21M | ﹤0.01% | 5005 |
|
|
2021
Q2 | $2.2M | Buy |
553,727
+195,685
| +55% | +$782K | ﹤0.01% | 4553 |
|
|
2021
Q1 | $1.86M | Buy |
358,042
+323,269
| +930% | +$1.72M | ﹤0.01% | 4303 |
|
|
2020
Q4 | $186K | Sell |
34,773
-608,110
| -95% | -$3.64M | ﹤0.01% | 5628 |
|
|
2020
Q3 | $3.12M | Buy |
642,883
+586,243
| +1,035% | +$3.83M | ﹤0.01% | 3211 |
|
|
2020
Q2 | $275K | Buy |
56,640
+36,926
| +187% | +$170K | ﹤0.01% | 4916 |
|
|
2020
Q1 | $43K | Sell |
19,714
-303
| -2% | -$1.15K | ﹤0.01% | 5521 |
|
|
2019
Q4 | $116K | Buy |
20,017
+15,987
| +397% | +$83.2K | ﹤0.01% | 5607 |
|
|
2019
Q3 | $13K | Sell |
4,030
-13,293
| -77% | -$49.8K | ﹤0.01% | 6124 |
|
|
2019
Q2 | $73K | Buy |
17,323
+15,174
| +706% | +$77.7K | ﹤0.01% | 5455 |
|
|
2019
Q1 | $15K | Sell |
2,149
-5,871
| -73% | -$41.1K | ﹤0.01% | 6090 |
|
|
2018
Q4 | $51K | Sell |
8,020
-261
| -3% | -$3.29K | ﹤0.01% | 5755 |
|
|
2018
Q3 | $145K | Buy |
+8,281
| New | +$136K | ﹤0.01% | 5576 |
|
Other funds holding AQST
BCM
RI
SB
SCM
Morgan Stanley's AQST Position: Q2 2026 in Review
Morgan Stanley reduced its Aquestive Therapeutics (AQST) stake by 59% in Q2 2026, selling an estimated $3.93M and leaving 658,617 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #4659.
Morgan Stanley first reported a position in AQST in Q3 2018 and has held it in 32 quarters since. The position peaked at $11.4M in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.
- Morgan Stanley held 658,617 shares of Aquestive Therapeutics worth $2.74M as of Q2 2026.
- Morgan Stanley sold 933,175 Aquestive Therapeutics shares in Q2 2026, an estimated $3.93M.
- Aquestive Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4659 holding.
- Morgan Stanley first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 32 quarters since.
- Morgan Stanley's Aquestive Therapeutics position peaked at $11.4M in Q4 2025.
- 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.